Yildiz Senol, Uluutku Haldun, Gunay Alp, Yildirim Ismail, Yildirim Sukru, Gurbuz Ahmet Kemal
Department of Sea and Underwater Medicine, Gulhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey.
Eur J Gastroenterol Hepatol. 2004 May;16(5):475-8. doi: 10.1097/00042737-200405000-00007.
Octreotide, a long-acting somatostatin analogue, has been used in the treatment of various disorders. Octreotide has significant detrimental impacts upon wound healing. We tested the hypothesis that hyperbaric oxygen therapy may overcome octreotide-mediated suppression of wound healing.
Prospective, randomised, parallel-group animal study.
Operated rats were divided into four groups: (1) controls, (2) octreotide therapy, (3) hyperbaric oxygen therapy and (4) combination of octreotide and hyperbaric oxygen therapy. Wound healing was assessed by breaking-strength measurements, hydroxyproline levels and fibrosis scores.
Octreotide decreased the breaking-strength measurements, hydroxyproline levels and fibrosis scores to 72%, 88% and 55%, respectively, of the control group. In the combination group, hyperbaric oxygen therapy increased breaking-strength measurements and hydroxyproline levels to 137% and 126%, respectively, of the control group. In the combination group, hyperbaric oxygen therapy tended to increase the fibrosis scores to 111% of the control group, but without statistical significance.
Hyperbaric oxygen therapy tends to reverse the octreotide-induced impairment of wound healing.
